Obesity, Diabetes Mellitus and Metabolic Syndrome
A section of Endocrines (ISSN 2673-396X).
Section Information
This section welcomes researchers interested in the aetiology, pathogenesis, and clinical aspects related to the prevention, diagnosis, monitoring, and treatment of obesity, diabetes mellitus, and metabolic syndrome. Priority areas include genetic and epigenetic drivers, multi-omics profiles, gut–brain–adipose signalling, microbiome shifts, dietary and psychosocial factors, endocrine disruptors, intergenerational influences on metabolic dysfunction, and the cellular and molecular circuits governing energy balance and insulin action.
We also welcome research on innovative therapies, including peptides, small molecules, antibodies, RNA- or gene-editing tools, microbiota-derived metabolites, nutraceuticals, and repurposed drugs, whether used alone or combined with lifestyle, digital, or device-based strategies. Submissions advancing precision medicine, such as the discovery and validation of novel biomarkers, molecular endotyping, head-to-head comparisons, or real-world effectiveness studies and those promoting health equity in underserved populations are particularly encouraged.
Spanning basic, translational, and clinical research, this section aims to accelerate the development of effective and equitable solutions to the global metabolic disease burden.
Manuscript formats: original research articles and reviews (systematic, literature, or narrative).Editorial Board
Special Issue
Following special issue within this section is currently open for submissions:
- Recent Advances in Type 1 Diabetes (Deadline: 31 March 2026)
